Twist Bioscience (NASDAQ:TWST) Shares Gap Down – What’s Next?

Twist Bioscience Corporation (NASDAQ:TWST)’s stock price gapped down before the market opened on Thursday. The stock had previously closed at $122.59, but opened at $99.72. Twist Bioscience shares last traded at $106.9530, with a volume of 1,497,585 shares.

Twist Bioscience News Summary

These are some of the TWST news items that stood out recently:

• Positive Sentiment: Fiscal Q4 revenue rose 26.7% year over year to $126.64 million, topping estimates, while the $0.32-per-share loss was narrower than consensus forecasts. Article
• Positive Sentiment: Management forecast Q1 fiscal 2027 revenue of $130 million–$132 million, above the $126.3 million consensus estimate. Full-year revenue guidance of $550 million–$560 million also modestly exceeded the $549 million consensus. Article
• Negative Sentiment: Despite those headline beats, coverage described the FY2027 outlook as underwhelming, suggesting it did not meet investor expectations. Continued losses and cost pressure may also have weighed on sentiment, helping explain the stock’s decline. Article

Analysts Set New Price Targets

Several analysts have recently issued reports on the stock. Guggenheim lifted their target price on shares of Twist Bioscience from $107.00 to $212.00 and gave the company a “buy” rating in a research report on Thursday, October 1st. BWS Financial reaffirmed a “sell” rating and issued a $45.00 price target on shares of Twist Bioscience in a research note on Friday, September 18th. TD Cowen raised their price target on shares of Twist Bioscience from $115.00 to $190.00 and gave the company a “buy” rating in a research note on Tuesday, October 13th. UBS Group started coverage on Twist Bioscience in a report on Wednesday, September 9th. They issued a “neutral” rating and a $144.00 price objective on the stock. Finally, Robert W. Baird boosted their price objective on Twist Bioscience from $113.00 to $115.00 and gave the stock an “outperform” rating in a research note on Tuesday, August 4th. Seven equities research analysts have rated the stock with a Buy rating, three have issued a Hold rating and two have issued a Sell rating to the stock. Based on data from MarketBeat.com, Twist Bioscience presently has a consensus rating of “Hold” and a consensus target price of $153.00.

Twist Bioscience Stock Down 8.9%

The company has a current ratio of 2.67, a quick ratio of 2.38 and a debt-to-equity ratio of 0.03. The business has a fifty day simple moving average of $150.90 and a two-hundred day simple moving average of $92.37. The company has a market cap of $7.00 billion, a PE ratio of -50.64 and a beta of 2.25.

Twist Bioscience (NASDAQ:TWST) last released its earnings results on Thursday, November 12th. The company reported ($0.32) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.39) by $0.07. The business had revenue of $126.64 million during the quarter, compared to analyst estimates of $123.55 million. Twist Bioscience had a negative net margin of 31.66% and a negative return on equity of 28.64%. The business’s revenue was up 26.7% compared to the same quarter last year. As a group, equities research analysts predict that Twist Bioscience Corporation will post -2.11 earnings per share for the current year.

Insider Buying and Selling at Twist Bioscience

In related news, CEO Emily M. Leproust sold 356,546 shares of the company’s stock in a transaction dated Thursday, September 17th. The shares were sold at an average price of $157.99, for a total transaction of $56,330,702.54. Following the completion of the sale, the chief executive officer owned 620,589 shares of the company’s stock, valued at approximately $98,046,856.11. This represents a 36.49% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Adam Laponis sold 8,057 shares of the stock in a transaction dated Friday, October 2nd. The shares were sold at an average price of $188.88, for a total transaction of $1,521,806.16. Following the completion of the sale, the chief financial officer owned 100,576 shares of the company’s stock, valued at approximately $18,996,794.88. The trade was a 7.42% decrease in their position. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last ninety days, insiders have sold 495,279 shares of company stock valued at $80,489,387. Insiders own 3.08% of the company’s stock.

Institutional Investors Weigh In On Twist Bioscience

Large investors have recently made changes to their positions in the stock. E Fund Management Hong Kong Co. Ltd. acquired a new stake in shares of Twist Bioscience in the 3rd quarter worth $280,000. Westpac Banking Corp boosted its position in shares of Twist Bioscience by 156.7% during the 3rd quarter. Westpac Banking Corp now owns 15,660 shares of the company’s stock valued at $3,026,000 after acquiring an additional 9,560 shares during the last quarter. Private Advisor Group LLC acquired a new position in shares of Twist Bioscience during the 3rd quarter valued at about $523,000. Ieq Capital LLC boosted its position in shares of Twist Bioscience by 7.5% during the 3rd quarter. Ieq Capital LLC now owns 54,948 shares of the company’s stock valued at $10,618,000 after acquiring an additional 3,839 shares during the last quarter. Finally, Stephens Investment Management Group LLC grew its holdings in shares of Twist Bioscience by 1.7% in the third quarter. Stephens Investment Management Group LLC now owns 780,419 shares of the company’s stock valued at $150,808,000 after purchasing an additional 13,055 shares during the period.

Twist Bioscience Company Profile

Twist Bioscience Corporation is a biotechnology company that uses a silicon-based platform to manufacture synthetic DNA. Its technology supports the production of many DNA sequences in parallel for research and commercial applications. The company provides synthetic genes, gene fragments and oligonucleotide pools, as well as tools for next-generation sequencing, including target-enrichment products. Through its biopharma business, Twist also offers antibody discovery and related services to support the development of therapeutics.